default author photo

Laura van't Veer

University of California, San Francisco (UCSF)

CA

United States

SCHOLARLY PAPERS

2

DOWNLOADS

148

TOTAL CITATIONS

3

Scholarly Papers (2)

1.

70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT

Number of pages: 22 Posted: 23 Oct 2020
Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of California, San Francisco (UCSF), European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Gustave Roussy Villejuif, Université Paris VI Pierre et Marie Curie - Institut Curie, Catholic University of Louvain (UCL) - CHU Site Sainte-Elisabeth, Institut Curie - Department of Medical Oncology, Noordwest Ziekenhuisgroep, Alrijne Ziekenhuis, Centre Georges-Francois Leclerc, Jeroen Bosch Ziekenhuis, European Institute of Oncology (IEO) IRCCS, Agendia, University of Lausanne - Swiss Institute of Bioinformatics (SIB), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of Navarra - Clínica Universidad de Navarra, Kliniken Essen-Mitte - Breast Unit, Università degli Studi di Genova - Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Baylor College of Medicine, Institute of Oncology, University of Lausanne - Lausanne University Hospital, Breast International Group Headquarters, Breast International Group Headquarters, University of Texas Health Science Center at San Antonio, Europa Donna-European Breast Cancer Coalition, Merck & Co., Inc., European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Champalimaud Foundation - Champalimaud Clinical Center and Netherlands Cancer Institute
Downloads 94 (720,278)
Citation 3

Abstract:

Loading...

breast cancer, genomics, adjuvant treatment, clinical trial

2.

Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial

Number of pages: 41 Posted: 19 Dec 2020
Yale University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Moffitt Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Diego (UCSD), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), University of Colorado, The University of Minnesota, University of Chicago, Loyola University of Chicago - Stritch School of Medicine, University of Pennsylvania, Oregon Health and Science University, Columbia University, Georgetown University, Wake Forest University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), George Mason University, George Mason University, Quantum Leap Healthcare Collaborative, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Berry Consultants, LLC, Berry Consultants, LLC, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), Gemini Group, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Diego (UCSD), University of Texas at Houston - MD Anderson Cancer Center, The University of Minnesota, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Pennsylvania, Berry Consultants, LLC and University of California, San Francisco (UCSF)
Downloads 54 (1,031,043)

Abstract:

Loading...

Breast cancer; immunotherapy; DNA repair inhibitor; clinical trial